BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 25, 2008
 |  BioCentury  |  Strategy

Biocon moves into Europe

Biocon Ltd. has been manufacturing active pharmaceutical ingredients since it was founded in 1978 but is now better known for its biologics, which it sells itself in India and through partners in South America, Asia and the Middle East. Armed with this experience and bolstered by what it sees as a shift in the global dynamics of public healthcare, the company is moving to expand its reach in the biosimilars space to Europe through its acquisition of 70% of AxiCorp GmbH.

Biocon's first marketed biologic is Insugen, a biosimilar recombinant insulin that was approved in India in 2004. The company has since received approval in India for three other biosimilars: Erypro erythropoietin (EPO) to treat anemia; Nufil filgrastim, a granulocyte-colony stimulating factor (G-CSF) to treat neutropenia; and the thrombolytic agent Myokinase streptokinase.

The first step to Biocon's global strategy for biosimilars was to partner out the marketing and distribution of its products, with the eventual goal of acquiring companies that do those functions.

Insugen is marketed by partners in about 10 countries worldwide, and Biocon hopes to expand that to more than 20 by year end. Biocon also is in the process of getting registration for Erypro, Nufil and Myokinase in the same regions.

Chairman and Managing Director Kiran Mazumdar-Shaw told BioCentury that Biocon now has the experience to take its branded biosimilars global. "We always planned to...

Read the full 1124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >